WO2005113620A1 - 生体適合性材料 - Google Patents
生体適合性材料 Download PDFInfo
- Publication number
- WO2005113620A1 WO2005113620A1 PCT/JP2005/009086 JP2005009086W WO2005113620A1 WO 2005113620 A1 WO2005113620 A1 WO 2005113620A1 JP 2005009086 W JP2005009086 W JP 2005009086W WO 2005113620 A1 WO2005113620 A1 WO 2005113620A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meth
- formula
- biocompatible material
- acrylate
- value
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
- C08F220/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/12—Esters of monohydric alcohols or phenols
- C08F220/16—Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms
- C08F220/18—Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids
- C08F220/1804—C4-(meth)acrylate, e.g. butyl (meth)acrylate, isobutyl (meth)acrylate or tert-butyl (meth)acrylate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/902—Method of implanting
- Y10S623/903—Blood vessel
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/92—Method or apparatus for preparing or treating prosthetic
- Y10S623/921—Blood vessel
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/924—Material characteristic
- Y10S623/926—Synthetic
Definitions
- the present invention relates to a biocompatible material.
- a biocompatible material for more information, see Foods, Food Additives, Pharmaceuticals
- the present invention relates to a biocompatible material that can be suitably used for quasi-drugs, medical devices, cosmetics, toiletries, and the like.
- Biocompatible materials are expected to be applied in various fields.
- artificial materials such as silicone, polyethylene, and polyurethane are used in medical devices such as medical tubes and catheters.
- these materials are recognized by the living body as foreign substances, and may be denatured by the adsorption of proteins and blood cells on the surface, or the materials themselves may be activated to induce rejection reactions such as blood coagulation. .
- glycine-type betaine coagulant which is obtained by betaine formation with monosodium acetate or the like (see, for example, Patent Documents 1 to 3).
- Patent Document 1 Japanese Patent Application Laid-Open No. 51-9732
- Patent Document 2 Japanese Patent Application Laid-Open No. 55-104209
- Patent Document 3 Japanese Patent Laid-Open No. 56-92809
- the present invention has been made in view of the above-described conventional technology, and has a small interaction with biological components such as proteins and blood cells for the development of next-generation advanced medical devices and artificial organs. It is an object to provide a biocompatible material having excellent compatibility. Means for solving the problem
- the present invention provides a compound of formula (I):
- R 1 is a hydrogen atom or a methyl group
- R 2 is an alkylene group having 1 to 6 carbon atoms
- IT and R 4 are each independently an alkyl group having 1 to 4 carbon atoms
- R 5 is carbon.
- An alkylene group of 1 to 4 and Z represents an oxygen atom or an NH group
- R 1 is the same as described above.
- R. represents a monovalent organic group.
- biocompatible material which has a polymer power which polymerizes the monomer composition containing the polymerizable monomer represented by these by the weight ratio (amino acid type betaine monomer Z polymerizable monomer) of 1Z99-: L00Z1.
- the biocompatible material of the present invention has excellent biocompatibility such as a flaw that does not interact with biological components such as proteins and blood cells for the development of next-generation advanced medical devices and artificial organs. Is. Since the biocompatible material of the present invention uses the betaine monomer represented by the formula (I), there is a point IJ that the molecular design according to the use can be freely performed. Brief Description of Drawings
- FIG. 1 is a graph showing the results of evaluation of nonspecific adsorption of bovine serum albumin (d ⁇ Ep) in Experimental Example 1.
- FIG. 2 is a graph showing the results of evaluation ( ⁇ I) of nonspecific adsorption of bovine serum albumin in Experimental Example 1.
- FIG. 3 is a graph showing the results of evaluation of nonspecific adsorption of lysozyme (d ⁇ Ep) in Experimental Example 1.
- R 1 represents a hydrogen atom or a methyl group.
- R 2 represents an alkylene group having 1 to 6 carbon atoms.
- R 3 and R 4 each independently represents an alkyl group having 1 to 4 carbon atoms.
- R 5 represents an alkylene group having 1 to 4 carbon atoms.
- Z represents an oxygen atom or an NH group.
- betaine monomer represented by the formula (I) include N— (meth) attaroyloxymethylinole N, N dimethylenolean mu-mu ⁇ — ⁇ -methinoleo power norboxoxybetaine, ⁇ - (me ) Ataliloylochetyl ⁇ , ⁇ Dimethylammo-mu ⁇ - ⁇ -Methylcarboxybetaine, ⁇ - (Meth) attayllooxypropyl- ⁇ , ⁇ ⁇ ⁇ ⁇ Dimethylammo-mu ⁇ - ⁇ -Methylcarboxybetaine, ⁇ - (meth) Atari Roy Ruo carboxymethyl over New, New - Jechiruanmo - ⁇ beam one alpha -Nyu- methyl carboxy betaine, Nyu- (meth) Atariroi Ruokishechiru New, New Jechiruanmo - Umu alpha-New methylcarboxy base tie
- (meta) atari means “atari” or “meta atari”.
- N-methacryloyloxychetyl N, N dimethylammonium ⁇ ⁇ methylcarboxybetaine represented by the following formula is preferred.
- Beta-monomers represented by the formula (I) typified by ⁇ -methacryloyloxychetilu ⁇ , ⁇ -dimethylammonium-a ⁇ -methylcarboxybetaine are, for example, JP-A-9-95474 and JP-A-9 As described in Japanese Patent No. 95586, Japanese Patent Laid-Open No. 11-222470, etc., it can be easily handled with high purity by this method.
- R 1 is the same as described above.
- R 6 represents a monovalent organic group. Typical examples of R 6 include COOR 7 group (R 7 represents an alkyl group having 1 to 22 carbon atoms), COO—R 8 — ⁇ group (R 8 represents an alkyl group having 1 to 4 carbon atoms) ), C ONR 9 R 1G group (R 9 and R 1G each independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms), OCO—R 11 group (R 11 is a methyl group or ethyl group) Group), formula (IV):
- R is an alkyl group having 2 to 9 carbon atoms, R 14 is a hydrogen atom or a methyl group
- R 6 COO— R 8 — OH group
- COOR Seven groups CONR 9 R 1C> group and the group represented by the formula (IV) are preferred from the viewpoint of biocompatibility.
- polymerizable monomer represented by the formula (II) include methyl (meth) acrylate, ethyl (meth) acrylate, n-butyl (meth) acrylate, isobutyl (meth) acrylate, T-butyl (meth) acrylate, neopentyl (meth) acrylate, cyclohexyl (meth) acrylate, benzyl (meth) acrylate, octyl (meth) acrylate, lauryl (meth) acrylate, (meth) acrylic Stearyl acid, cetyl (meth) acrylate, ethyl carbitol (meth) acrylate, hydroxyethyl (meth) acrylate, hydroxypropyl (meth) acrylate, hydroxybutyl (meth) acrylate, (meth) acrylic Methoxyethyl acid, methoxybutyl (meth)
- polymerizable monomers represented by the formula (II) from the viewpoint of biocompatibility, butyl (meth) acrylate, stearyl (meth) acrylate, N, N-dimethylacrylamide, N-bulu pyrrolidone , Hydroxyethyl (meth) acrylate, etc. are preferred.
- the amount of the betaine monomer represented by the formula (I) and the polymerizable monomer represented by the formula (II) varies depending on the body part where the biocompatible material is used, the purpose of use, etc.
- the betaine monomer represented by formula (I) Z is represented by the formula represented by formula ( ⁇ ).
- the monomer (weight ratio) is adjusted to be 1Z99 to: LOOZO, preferably 5Z95 95Z5, more preferably 10/90 90/10.
- the resulting polymer is a homopolymer of the betaine monomer represented by the formula (I).
- the monomer composition is composed of a betaine monomer represented by the formula (I) and a polymerizable monomer represented by the formula (II)
- the resulting polymer is represented by the formula (I).
- the betaine monomer is a copolymer of a polymerizable monomer represented by the formula (II).
- the polymer constituting the biocompatible material can be prepared, for example, by polymerizing the monomer composition by solution polymerization using water or an organic solvent as a solvent. More specifically, a monomer composition containing a predetermined amount of a betaine monomer represented by the formula (I) and a polymerizable monomer represented by the formula (II) was dissolved in purified water or an organic solvent. While stirring the solution, it can be obtained by adding a polymerization initiator to the solution and polymerizing the monomer composition in an inert gas atmosphere.
- Examples of the organic solvent include alcohols such as methyl alcohol, ethyl alcohol, isopropyl alcohol, ethylene glycol, and propylene glycol, ketones such as acetone and methyl ethyl ketone, jetyl ether, and tetrahydrofuran.
- Alkyl ethers aromatic compounds such as benzene, toluene and xylene, aliphatic hydrocarbon compounds such as n-xane, alicyclic hydrocarbon compounds such as cyclohexane, methyl acetate, ethyl acetate, etc. Powers such as acetate esters The present invention is not limited to powerful examples.
- the concentration of the monomer composition in the monomer composition solution used for solution polymerization is preferably about 10 to 80% by weight in consideration of the operability of polymerization.
- a polymerization initiator is preferably used.
- the polymerization initiator is not particularly limited.
- ordinary azo compounds such as azoisobutyric-tolyl, methyl azoisobutyrate, azobisdimethylvalero-tolyl, benzoyl peroxide, potassium persulfate, and ammonium persulfate.
- Photopolymerization initiators such as benzophenone derivatives, phosphine oxide derivatives, benzoketone derivatives, phenol thioether derivatives, azide derivatives, diazo derivatives, disulfide derivatives, etc. Is mentioned.
- the amount of the polymerization initiator is usually preferably about 0.01 to 5 parts by weight with respect to 100 parts by weight of the monomer composition.
- a chain transfer agent can be used as necessary.
- the chain transfer agent include compounds having a mercaptan group such as lauryl mercaptan, dodecyl mercaptan, and thioglycerol, and inorganic salts such as sodium hypophosphite and sodium bisulfite. It is not limited to only.
- the amount of chain transfer agent is usually preferably about 0.01 to 10 parts by weight per 100 parts by weight of the monomer composition.
- the polymerization temperature of the monomer composition varies depending on the type of polymerization initiator used, and thus cannot generally be determined. However, it is usually preferable to set the polymerization initiator to the 10-hour half-life temperature.
- the polymerization time is desirably 2 hours or more, preferably about 2 to 24 hours, from the viewpoint of avoiding remaining unreacted monomers.
- the polymerization of the monomer composition can be performed in an inert gas atmosphere. Examples of the inert gas include nitrogen gas and argon gas.
- a polymer can be obtained by polymerizing the monomer composition by force.
- the obtained polymer can be recovered by fractionation using an ultrafiltration membrane or the like and, if necessary, washing by a conventional method.
- the weight average molecular weight of the obtained polymer is determined by the handleability during production and the processability of the product.
- the viewpoint power is preferably 5 to 2 million, more preferably 1000 to 100 million.
- the biocompatible material of the present invention comprises the polymer.
- the biocompatible material of the present invention may be composed of the polymer and another polymer as long as the object of the present invention is not hindered if necessary. Moyo!
- biocompatible material of the present invention is excellent in biocompatibility! /, It is suitable for, for example, foods, food additives, pharmaceuticals, quasi-drugs, medical devices, cosmetics, toiletries, etc. It can be used.
- Examples of foods and food additives include thickeners, pH adjusters, molding aids, and packaging materials used in ordinary foods.
- Examples of pharmaceuticals, quasi-drugs, and medical devices include drug delivery system agents, artificial blood vessels, hemodialysis membranes, force tapes, contact lenses, blood filters, blood storage packs, and artificial organs.
- Cosmetic and toiletry products include, for example, shampoos, rinses, conditioners, emulsions, water retention creams, sarcophagus, skin cleansing agents, nocturnal agents, cortical release agents, hair styling agents, hair dyes, hair bleaching agents, Permanent agents, perfumes, antiperspirants, fresheners, disposable diapers, sanitary products, bath cleaners, dish cleaners, tap water filtration filters, etc. S, the present invention is limited to powerful examples only Is not to be done.
- Example 1 the present invention is limited to powerful examples only Is not to be done.
- 11.9 mg of tetraethylthiuram disulfide as a photopolymerization initiator was added, and then dissolved in a mixed solvent of 2.5 mL of methanol and 1 mL of tetrahydrofuran. Nitrogen gas was added to the resulting solution. After passing for 15 minutes, the monomer composition was photopolymerized by irradiating with ultraviolet rays for 4 hours in a nitrogen gas atmosphere at a temperature of 25 ° C.
- Example 1 as a monomer composition, a mixture of butyl methacrylate and N-methacryloyloxychetilu N, N dimethylammo- ⁇ - ⁇ methylcarboxybetaine (butyl methacrylate) ⁇ -methacryloyloxychetyl ⁇ , ⁇ ⁇ ⁇ ⁇ dimethyl A polymer was obtained in the same manner as in Example 1 except that 250 mg of ammonia- ⁇ - ⁇ -methylcarboxybetaine weight ratio: 4Z6] was used.
- fractionation was performed by ultrafiltration (fractionated molecular weight 3000 to L0000), and the resulting polymer was recovered by freeze-drying (yield 50 mg).
- yield 50 mg When the weight average molecular weight of the obtained polymer was examined by H 1 -NMR, it was 18000.
- the weight average molecular weight of the obtained polymer was examined by gel permeation chromatography (mobile phase: 0.1M aqueous solution of sodium bromide containing 0.5% lithium bromide), it was 114 00.
- Example 2 instead of N-methacryloyloxychetyl N, N dimethylammonium a N methylcarboxybetaine 5.0 g, N-methacryloyloxychetti R, N, N Dimethylammo-mu ⁇ - ⁇ ⁇ ⁇ Methylcarboxybetaine and Butylmetatalylate 2. 23 mL (N-Methacryloyloxychetil ⁇ , N The polymer was polymerized at 70 ° C for 24 hours using a weight ratio of 45 to 5 5), then poured into n-hexane to precipitate, further dissolved in water and fractionated by dialysis (fraction molecular weight 3500).
- the resulting polymer was recovered by lyophilization (yield 1.6 g). 0
- the weight average molecular weight of the obtained polymer was determined by gel permeation chromatography (mobile phase: containing 0.5% lithium bromide 0 It was 17800 when examined by 1M sodium bromide aqueous solution.
- Example 1 except that 234 mg of methacrylic acid was used instead of 234 mg of N-methacryloyloxychetyl N, N dimethylammonium a N-methylcarboxybetaine, the polymer was prepared in the same manner as in Example 1. Obtained. When the degree of polymerization and the weight average molecular weight of the obtained polymer were examined by H 1 -NMR, the degree of polymerization was 16, and the weight average molecular weight was 2,700.
- poly L-lysine hydrogen bromide (weight average molecular weight: 2700) was used.
- polyethylene glycol weight average molecular weight: 2000
- Example 1 the self-assembled monolayers of the polymers obtained in Example 1 and Comparative Example 1 were used. I examined the cyclic voltammary.
- a gold electrode (AUE6.0.0x1.6 mm; BAS) was polished with alumina powder, and then this gold electrode was irradiated with ultrasonic waves (Sine Sonicl 50, Sine) for 30 seconds. .
- a cyclic 'Voltammogram (potentio stat: manufactured by Hokuto Denki Co., Ltd., product number: HA-301), a functional generator (manufactured by Hokuto Denko Co., Ltd., product number: HA— 104], applying voltage by immersing the electrode in 0.1N sulfuric acid aqueous solution or 0.5N potassium hydroxide aqueous solution using a power source and AC-DC conversion (Epson, product number: PC-486 SE) did.
- 0.1N sulfuric acid aqueous solution a voltage of -0.4 to 1.5V is applied
- 0.5N potassium hydroxide aqueous solution a voltage of 0 to -1.5V is applied.
- 0.1N sulfuric acid aqueous solution a voltage of -0.4 to 1.5V is applied
- 0.5N potassium hydroxide aqueous solution a voltage of 0 to -1.5V is applied. Applied.
- the gold electrode was immersed in an aqueous solution containing 0.5M potassium chloride and 5mM hexaxanoic iron (III) potassium, and the sweep rate lOmVZs and applied voltage were After examining the cyclic voltammogram at 0.6 to 1 to 0.3 V and confirming that the potential difference (hereinafter referred to as ⁇ Ep and!) Was 1 ⁇ 25 mV or less, this gold electrode was used.
- the gold electrode was immersed in lmgZmL of the aqueous solution of the material obtained in Example 1 and Comparative Example 1 for 24 hours, and then washed several times with purified water.
- the gold electrode obtained by modifying the material obtained in Example 1 and Comparative Example 1 was prepared using a 10 mM phosphate buffer solution (hereinafter referred to as HQ solution) containing ImM hydroquinone and 0.1 M sodium sulfate and having a pH of 7.0. was used to observe nonspecific adsorption of proteins.
- HQ solution 10 mM phosphate buffer solution
- Bovine serum albumin (BSA, pi: 4.8, 66 kD) or lysozyme (pi: 10. 9, 1.4 kD) was dissolved in 10 mM phosphate buffer at pH 7.0 to obtain a protein solution (lmgZmL). .
- a protein solution (lmgZmL).
- the cyclic voltammogram was examined with the HQ solution, and the potential difference was defined as Om V. Thereafter, the sample was immersed in a protein solution, pulled up at regular intervals, rinsed several times with purified water, and then a cyclic voltammogram was measured with an HQ solution.
- FIG. 1 shows the result of evaluation of nonspecific adsorption of bovine serum albumin (d A Ep) in Experimental Example 1. From the results shown in Fig. 1, when using a gold electrode without a monomolecular film (Bare Au in Fig. 1) and Comparative Example 1, the value of dAEp increased while It can be seen that the value of d A Ep in Example 1 is almost unchanged near 0. From this, the gold electrode on which the self-assembled monolayer formed of the biocompatible material according to Example 1 is formed has a low amount of protein adsorbed on its surface, and thus has excellent biocompatibility. I understand
- FIG. 2 shows the results of evaluation of nonspecific adsorption ( ⁇ I) of bovine serum albumin in Experimental Example 1. From the results shown in Fig. 2, when a gold electrode without a monomolecular film was used (Bare Au in Fig. 2), the value of ⁇ I was significantly reduced, whereas Example 1 It can be seen that the value of ⁇ I at is almost unchanged. From this, the gold electrode formed with the self-assembled monolayer made of the biocompatible material according to Example 1 has a small amount of protein adsorbed on the surface, and thus has excellent biocompatibility. It ’s hard to do that.
- FIG. 3 shows the results of evaluation of nonspecific adsorption of lysozyme (d ⁇ Ep) in Experimental Example 1. From the results shown in Fig. 3, when a gold electrode without a monomolecular film was used (Bare Au in Fig. 3) and Comparative Example 1, the d A Ep value increased, but It can be seen that (1 ⁇ ⁇ « ⁇ ⁇ in Example 1 hardly changes. From this, the gold electrode on which the self-assembled monolayer made of the biocompatible material according to Example 1 is formed has its surface. Since the amount of protein adsorbed on the surface is small, it is extremely difficult to be biocompatible.
- the biocompatible material obtained in Example 1 is excellent in biocompatibility in which proteins such as bovine serum albumin and lysozyme are difficult to adsorb.
- the method is as follows.
- Pd indicates the possibility of eliminating O—H vibrations from the hydrogen bond network of water molecules due to unfavorable position and orientation due to solvent interaction.
- Pd is the formula:
- N value indicates the number of hydrogen bond defects introduced into the network of water hydrogen bonds per monomer unit of the polymer. N value is the formula:
- N value Pd / Fx
- the C value represents the relative intensity of collective O—H stretching vibration.
- the C value (C) for pure water is
- the N value is corrected by this factor because it is smaller than the C value for perfect ice (C).
- N value which is a correction value of N value is given.
- N value is the formula:
- N value (CWZC) X N value
- Ic I —I Z ⁇
- biocompatible material of the present invention is excellent in biocompatibility! /, It is suitable for, for example, foods, food additives, pharmaceuticals, quasi drugs, medical devices, cosmetics, toiletries, etc. Can be used.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Materials For Medical Uses (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/596,884 US7662898B2 (en) | 2004-05-20 | 2005-05-18 | Biocompatible material |
EP05741351A EP1760098B1 (en) | 2004-05-20 | 2005-05-18 | Biocompatible material |
JP2006513707A JP4719146B2 (ja) | 2004-05-20 | 2005-05-18 | 生体適合性材料 |
KR1020067026424A KR101201264B1 (ko) | 2004-05-20 | 2005-05-18 | 생체 적합성 재료 |
CN2005800158584A CN1954004B (zh) | 2004-05-20 | 2005-05-18 | 生物相容性材料 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-150693 | 2004-05-20 | ||
JP2004150693 | 2004-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005113620A1 true WO2005113620A1 (ja) | 2005-12-01 |
Family
ID=35428381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/009086 WO2005113620A1 (ja) | 2004-05-20 | 2005-05-18 | 生体適合性材料 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7662898B2 (ja) |
EP (1) | EP1760098B1 (ja) |
JP (1) | JP4719146B2 (ja) |
CN (1) | CN1954004B (ja) |
WO (1) | WO2005113620A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007130194A (ja) * | 2005-11-10 | 2007-05-31 | Osaka Organic Chem Ind Ltd | 医療用材料 |
JP2008115204A (ja) * | 2006-10-31 | 2008-05-22 | Chiba Univ | 防汚性物品および防汚性物品の製造方法 |
WO2008066381A1 (en) * | 2006-11-29 | 2008-06-05 | Procornea Holding B.V. | Hydrogel contact lens comprising a polymer comprising a carboxy betaine ester monomer |
JP2008274151A (ja) * | 2007-05-01 | 2008-11-13 | Teika Seiyaku Kk | 創傷被覆組成物および創傷被覆材 |
JP2009069141A (ja) * | 2007-08-23 | 2009-04-02 | Canon Inc | 構造体、標的物質検出素子および標的物質検出キット |
JP2010057745A (ja) * | 2008-09-04 | 2010-03-18 | Osaka Organic Chem Ind Ltd | 医療用材料 |
JP2012034747A (ja) * | 2010-08-04 | 2012-02-23 | Osaka Organic Chem Ind Ltd | 生体適合性材料 |
WO2015098763A1 (ja) | 2013-12-27 | 2015-07-02 | テルモ株式会社 | 医療用具 |
WO2016052618A1 (ja) * | 2014-10-02 | 2016-04-07 | 旭化成メディカル株式会社 | 生体由来液処理フィルター及びフィルターデバイス |
WO2016067795A1 (ja) * | 2014-10-29 | 2016-05-06 | 富士フイルム株式会社 | 生体物質非接着性材料、硬化性組成物、これらを用いた人工器官および医療器具 |
JP2017176616A (ja) * | 2016-03-31 | 2017-10-05 | 旭化成メディカル株式会社 | 生体由来液処理フィルター及びフィルターデバイス |
US9956324B2 (en) | 2014-02-24 | 2018-05-01 | Terumo Kabushiki Kaisha | Medical material, and medical device using the medical material |
WO2019078027A1 (ja) * | 2017-10-18 | 2019-04-25 | 富士フイルム株式会社 | 硬化性組成物、膜、硬化物、医療用部材 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013172292A1 (ja) * | 2012-05-12 | 2013-11-21 | 国立大学法人北海道大学 | 水性ゲル |
US10597540B2 (en) | 2013-05-27 | 2020-03-24 | Jsr Corporation | Surface treatment agent for surface configured from inorganic material, tool and device having modified surface, and method for manufacturing tool and device |
JP6580842B2 (ja) * | 2015-02-28 | 2019-09-25 | 大阪有機化学工業株式会社 | 化粧料 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0667122A (ja) * | 1992-08-18 | 1994-03-11 | Nippon Oil & Fats Co Ltd | ソフトコンタクトレンズ |
JPH07100356A (ja) * | 1993-09-30 | 1995-04-18 | Shiseido Co Ltd | 新規複合体及び乳化剤 |
JPH07300513A (ja) * | 1994-05-09 | 1995-11-14 | Nippon Oil & Fats Co Ltd | 表面グラフト化材料 |
JPH0995474A (ja) | 1995-07-21 | 1997-04-08 | Osaka Organic Chem Ind Ltd | ベタインモノマーの製法 |
JPH0995586A (ja) | 1995-07-21 | 1997-04-08 | Osaka Organic Chem Ind Ltd | 水溶性整髪用樹脂組成物およびその製法 |
JPH09310228A (ja) * | 1996-05-22 | 1997-12-02 | Toyobo Co Ltd | 複合構造を有する高塩水吸収性繊維及びその製造法 |
JPH10279918A (ja) * | 1997-03-31 | 1998-10-20 | Shiseido Co Ltd | 可溶化剤およびこれを含有する化粧料 |
JPH11130822A (ja) * | 1997-10-31 | 1999-05-18 | Kao Corp | 親水性重合体及びこれを含有する保湿剤 |
JPH11222470A (ja) | 1998-02-02 | 1999-08-17 | Osaka Organic Chem Ind Ltd | グリシンベタインモノマーの製法 |
JP2002068974A (ja) * | 2000-08-25 | 2002-03-08 | Pola Chem Ind Inc | 抗真菌医薬組成物 |
JP2002121227A (ja) * | 2000-10-11 | 2002-04-23 | Osaka Organic Chem Ind Ltd | 清涼感組成物およびそれからなる化粧料 |
JP2002322223A (ja) * | 2001-04-26 | 2002-11-08 | Osaka Organic Chem Ind Ltd | N−ビニル−2−ピロリドン含有樹脂組成物、その製法およびそれからなる化粧料 |
JP2002348205A (ja) * | 2001-05-25 | 2002-12-04 | Lion Corp | 皮膚外用剤組成物及び可溶化剤 |
JP2004339181A (ja) * | 2003-05-19 | 2004-12-02 | Goo Chemical Co Ltd | 消臭剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS519732A (ja) | 1974-07-08 | 1976-01-26 | Mitsubishi Petrochemical Co | Seihatsuyojushisoseibutsu |
JPS55104209A (en) | 1979-02-06 | 1980-08-09 | Mitsubishi Petrochem Co Ltd | Resin composition for hairdressing |
JPS5692809A (en) | 1979-12-27 | 1981-07-27 | Mitsubishi Petrochem Co Ltd | Resin for hair dressing |
-
2005
- 2005-05-18 EP EP05741351A patent/EP1760098B1/en not_active Ceased
- 2005-05-18 CN CN2005800158584A patent/CN1954004B/zh active Active
- 2005-05-18 JP JP2006513707A patent/JP4719146B2/ja active Active
- 2005-05-18 US US11/596,884 patent/US7662898B2/en active Active
- 2005-05-18 WO PCT/JP2005/009086 patent/WO2005113620A1/ja active Application Filing
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0667122A (ja) * | 1992-08-18 | 1994-03-11 | Nippon Oil & Fats Co Ltd | ソフトコンタクトレンズ |
JPH07100356A (ja) * | 1993-09-30 | 1995-04-18 | Shiseido Co Ltd | 新規複合体及び乳化剤 |
JPH07300513A (ja) * | 1994-05-09 | 1995-11-14 | Nippon Oil & Fats Co Ltd | 表面グラフト化材料 |
JPH0995474A (ja) | 1995-07-21 | 1997-04-08 | Osaka Organic Chem Ind Ltd | ベタインモノマーの製法 |
JPH0995586A (ja) | 1995-07-21 | 1997-04-08 | Osaka Organic Chem Ind Ltd | 水溶性整髪用樹脂組成物およびその製法 |
JPH09310228A (ja) * | 1996-05-22 | 1997-12-02 | Toyobo Co Ltd | 複合構造を有する高塩水吸収性繊維及びその製造法 |
JPH10279918A (ja) * | 1997-03-31 | 1998-10-20 | Shiseido Co Ltd | 可溶化剤およびこれを含有する化粧料 |
JPH11130822A (ja) * | 1997-10-31 | 1999-05-18 | Kao Corp | 親水性重合体及びこれを含有する保湿剤 |
JPH11222470A (ja) | 1998-02-02 | 1999-08-17 | Osaka Organic Chem Ind Ltd | グリシンベタインモノマーの製法 |
JP2002068974A (ja) * | 2000-08-25 | 2002-03-08 | Pola Chem Ind Inc | 抗真菌医薬組成物 |
JP2002121227A (ja) * | 2000-10-11 | 2002-04-23 | Osaka Organic Chem Ind Ltd | 清涼感組成物およびそれからなる化粧料 |
JP2002322223A (ja) * | 2001-04-26 | 2002-11-08 | Osaka Organic Chem Ind Ltd | N−ビニル−2−ピロリドン含有樹脂組成物、その製法およびそれからなる化粧料 |
JP2002348205A (ja) * | 2001-05-25 | 2002-12-04 | Lion Corp | 皮膚外用剤組成物及び可溶化剤 |
JP2004339181A (ja) * | 2003-05-19 | 2004-12-02 | Goo Chemical Co Ltd | 消臭剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1760098A4 |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007130194A (ja) * | 2005-11-10 | 2007-05-31 | Osaka Organic Chem Ind Ltd | 医療用材料 |
JP2008115204A (ja) * | 2006-10-31 | 2008-05-22 | Chiba Univ | 防汚性物品および防汚性物品の製造方法 |
WO2008066381A1 (en) * | 2006-11-29 | 2008-06-05 | Procornea Holding B.V. | Hydrogel contact lens comprising a polymer comprising a carboxy betaine ester monomer |
JP2008274151A (ja) * | 2007-05-01 | 2008-11-13 | Teika Seiyaku Kk | 創傷被覆組成物および創傷被覆材 |
JP2009069141A (ja) * | 2007-08-23 | 2009-04-02 | Canon Inc | 構造体、標的物質検出素子および標的物質検出キット |
JP2010057745A (ja) * | 2008-09-04 | 2010-03-18 | Osaka Organic Chem Ind Ltd | 医療用材料 |
JP2012034747A (ja) * | 2010-08-04 | 2012-02-23 | Osaka Organic Chem Ind Ltd | 生体適合性材料 |
JPWO2015098763A1 (ja) * | 2013-12-27 | 2017-03-23 | テルモ株式会社 | 医療用具 |
US10022478B2 (en) | 2013-12-27 | 2018-07-17 | Terumo Kabushiki Kaisha | Medical device |
WO2015098763A1 (ja) | 2013-12-27 | 2015-07-02 | テルモ株式会社 | 医療用具 |
US9956324B2 (en) | 2014-02-24 | 2018-05-01 | Terumo Kabushiki Kaisha | Medical material, and medical device using the medical material |
CN106794290A (zh) * | 2014-10-02 | 2017-05-31 | 旭化成医疗株式会社 | 源自生物体的液体处理过滤器及过滤器装置 |
WO2016052618A1 (ja) * | 2014-10-02 | 2016-04-07 | 旭化成メディカル株式会社 | 生体由来液処理フィルター及びフィルターデバイス |
US10780204B2 (en) | 2014-10-02 | 2020-09-22 | Asahi Kasei Medical Co., Ltd. | Biological fluid-treating filter and filter device |
JPWO2016067795A1 (ja) * | 2014-10-29 | 2017-10-05 | 富士フイルム株式会社 | 生体物質非接着性材料、硬化性組成物、これらを用いた人工器官および医療器具 |
WO2016067795A1 (ja) * | 2014-10-29 | 2016-05-06 | 富士フイルム株式会社 | 生体物質非接着性材料、硬化性組成物、これらを用いた人工器官および医療器具 |
US10385151B2 (en) | 2014-10-29 | 2019-08-20 | Fujifilm Corporation | Material non-adhesive to biological substance, curable composition, and artificial organ and medical instrument using same |
JP2017176616A (ja) * | 2016-03-31 | 2017-10-05 | 旭化成メディカル株式会社 | 生体由来液処理フィルター及びフィルターデバイス |
WO2019078027A1 (ja) * | 2017-10-18 | 2019-04-25 | 富士フイルム株式会社 | 硬化性組成物、膜、硬化物、医療用部材 |
JPWO2019078027A1 (ja) * | 2017-10-18 | 2020-11-26 | 富士フイルム株式会社 | 硬化性組成物、膜、硬化物、医療用部材 |
US11130831B2 (en) | 2017-10-18 | 2021-09-28 | Fujifilm Corporation | Curable composition, film, cured product, and medical member |
Also Published As
Publication number | Publication date |
---|---|
CN1954004B (zh) | 2010-08-18 |
US20080262181A1 (en) | 2008-10-23 |
EP1760098A4 (en) | 2008-05-07 |
EP1760098A1 (en) | 2007-03-07 |
EP1760098B1 (en) | 2012-01-18 |
JP4719146B2 (ja) | 2011-07-06 |
CN1954004A (zh) | 2007-04-25 |
US7662898B2 (en) | 2010-02-16 |
JPWO2005113620A1 (ja) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005113620A1 (ja) | 生体適合性材料 | |
Song et al. | Recent advances and future perspectives of synthetic polypeptides from N-carboxyanhydrides | |
JP4961133B2 (ja) | 医療用材料 | |
Mei et al. | Solid-phase ATRP synthesis of peptide− polymer hybrids | |
Mather et al. | Michael addition reactions in macromolecular design for emerging technologies | |
US10363340B2 (en) | Poly(oligoethylene glycol methacrylate) hydrogel compositions, and methods of use thereof | |
JP5133048B2 (ja) | 重合化合物及び関連した使用方法 | |
US10098984B2 (en) | Method for grafting polymers on metallic substrates | |
JP2011518907A (ja) | 改質されたハロゲン化ポリマー表面 | |
Preuss et al. | A bioinspired light induced avenue for the design of patterned functional interfaces | |
Divandari et al. | Controlling enzymatic polymerization from surfaces with switchable bioaffinity | |
KR101112756B1 (ko) | 광반응성 키토산 유도체 및 그의 용도 | |
US20110262492A1 (en) | Catalyst and byproduct-free native chemical ligation using cyclic thioester precursors | |
Musgrave III et al. | Computational and experimental evaluation of peroxide oxidants for amine–peroxide redox polymerization | |
Ma et al. | Surface Chemical Functionalization of Wrinkled Thiol–Ene Elastomers for Promoting Cellular Alignment | |
KR101201264B1 (ko) | 생체 적합성 재료 | |
JPWO2019078027A1 (ja) | 硬化性組成物、膜、硬化物、医療用部材 | |
JP5059340B2 (ja) | 生体適合性材料 | |
JP2018123275A (ja) | 細胞接着防止剤 | |
Laure et al. | Reversible tethering of polymers onto catechol-based titanium platforms | |
JP4931342B2 (ja) | 義歯床用コーティング材 | |
Tsai et al. | Functional Materials from Self‐Assembling Peptide–Polymer Hybrids | |
JP2008245747A (ja) | 表皮親和性コーティング剤及び医療用具 | |
Wilken | Poly (N-Vinylpyrrolidone) based biomimetic hydrogels | |
Chen et al. | Nanoscale Functional Polymer Coatings for Biointerface Engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006513707 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11596884 Country of ref document: US Ref document number: 200580015858.4 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067026424 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005741351 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067026424 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005741351 Country of ref document: EP |